Valley International Journal Digital Library

VIJ Digital library
Articles

IDMap: Leveraging AI and Data Technologies for Early Cancer Detection

PDF
  • Sabira Arefin
Sabira Arefin
CEO Idmap.ai Global Healthcare Leadership program Harvard Medical School Best Selling Author on Amazon Founder of Institute of Global Health
Published in : International Journal of Scientific Research and Management (IJSRM) , Vol. 12 No. 08 (2024)

Submission to VIJ 2024-08-04

Keywords

  • IDMap: Leveraging

Abstract

Cancer screening is vital in cutting mortality rates, and containing the impact of cancer in a worldwide basis. The current conventional detection techniques including imaging and biopsy though efficient are also characterized with drawbacks like; invasive, expensive, and inaccurate. This abstract will describe the new AI and data solution in the fight against early cancer detection, which presents a massive opportunity to improve accuracy, cut down the time that it takes to deliver a diagnosis, and bring quality health care to possibly millions of patients. ML and, in particular, DL are prospective in terms of decision making upon medical data including imaging, genomic sequences, and electronic health records to detect biomarkers of cancer in early stages. The statistics show that the AI-driven systems are capable to provide better diagnostic outcomes than conventional methods in some fields including mammography for breast cancer and CT for lung. Moreover, AI’s integration in genomic studies helps in determining Cancer related genes and biomarkers hence supporting precision medicine that adapts treatment to the specific genetic information of the patient. Apart from having outlets in AI, big data analytics, cloud computing, and IoT are equally important in early cancer detection as well. Big data analysis enables the analysis of large and complicated data sets with the aid of which one may identify inklings that may point towards possible early development of cancer. The use of cloud computing in health care mainly provides meaningful platforms for the storage and management of the large volumes of medical data in a way that allows improved efficiency and high levels of security. Wearable sensors collect data on different biomarkers throughout a patient’s body, and convey real-time information regarding whether the biomarkers’ levels are approaching cancerous state. Despite this great promise, there are various issues that have to be solved: data protection, privacy, and security, problems with the algorithms’ biases, and integration into practice. Ethical questions are generally important to tackle the uncertainty surrounding data and decision-making in clinical care using A I systems. The future trends in early cancer diagnostics will involve deeper integration of the approaches as AI and big data technology, which will enable more precise prevention and treatment. The applicability of this approach can also extend to the early identification of cancer, but also the prevention of its occurrence through proper intervention. In conclusion, conversing AI and data technologies will be useful for enhancing the efficiency of the early cancer diagnosis, and that is why the perspectives for the patients’ recovery and the further decrease in the mortality rates connected with cancer are rather promising. The approaches in this area remain informative developing technologies that are likely to be integrated into clinical work as the leading organizational models for the future of oncology and preventive health.

PDF

References

  1. Rodrigues, V. C., Soares, J. C., Soares, A. C., Braz, D. C., Melendez, M. E., Ribas, L. C., ... & Oliveira Jr, O. N. (2021). Electrochemical and optical detection and machine learning applied to images of genosensors for diagnosis of prostate cancer with the biomarker PCA3. Talanta, 222, 121444.
  2. Cruz-Pacheco, A. F., Echeverri, D., & Orozco, J. (2023). Role of electrochemical nanobiosensors in colorectal cancer precision medicine. TrAC Trends in Analytical Chemistry, 117467.
  3. Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016). A survey of current trends in computational drug repositioning. Briefings in bioinformatics, 17(1), 2-12.
  4. Arefin, S. (2024). Health Equity and Solutions in the United States Healthcare System. Integrated Journal of Science and Technology, 1(5), 1-9.
  5. Wu, Y., Warner, J. L., Wang, L., Jiang, M., Xu, J., Chen, Q., ... & Xu, H. (2019). Discovery of noncancer drug effects on survival in electronic health records of patients with cancer: a new paradigm for drug repurposing. JCO clinical cancer informatics, 3, 1-9.
  6. Allarakhia, M. (2013). Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Design, Development and Therapy, 753-766.
  7. Pazin, W. M., Furini, L. N., Braz, D. C., Popolin-Neto, M., Fernandes, J. D., Leopoldo Constantino, C. J., & Oliveira Jr, O. N. (2024). Explainable Machine Learning to Unveil Detection Mechanisms with Au Nanoisland-Based Surface-Enhanced Raman Scattering for SARS-CoV-2 Antigen Detection. ACS Applied Nano Materials, 7(2), 2335-2342.
  8. Kraus, C. N. (2008). Low hanging fruit in infectious disease drug development. Current opinion in microbiology, 11(5), 434-438.
  9. Veras, A. S. C., Batista, V. R. G., Correia, R. R., de Almeida Tavares, M. E., Rubira, R. J. G., Tavares, E. R., ... & Teixeira, G. R. (2024). Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression. Scientific Reports, 14(1), 9626.
  10. Campbell, S. J., Gaulton, A., Marshall, J., Bichko, D., Martin, S., Brouwer, C., & Harland, L. (2010). Visualizing the drug target landscape. Drug discovery today, 15(1-2), 3-15.
  11. Dennig, F. L., Miller, M., Keim, D. A., & El-Assady, M. (2023). FS/DS: A theoretical framework for the dual analysis of feature space and data space. IEEE Transactions on Visualization and Computer Graphics.
  12. Naylor, S., & Cole, T. Sidebar Banner 6 Sidebar Banner 7 Sidebar Banner 8 Sidebar Banner 12 Sidebar Banner 18.
  13. Karthikeyan, M., Pandit, Y., Pandit, D., & Vyas, R. (2015). MegaMiner: a tool for lead identification through text mining using chemoinformatics tools and cloud computing environment. Combinatorial Chemistry & High Throughput Screening, 18(6), 591-603.
  14. Harland, L., & Gaulton, A. (2009). Drug target central. Expert Opinion on Drug Discovery, 4(8), 857-872.
  15. KUMAR, P. (2009). Database development and machine learning classification of medicinal chemicals and biomolecules.
  16. Kushida, T., Mendes de Farias, T., Sima, A. C., Dessimoz, C., Chiba, H., Bastian, F., & Masuya, H. (2023). Exploring Disease Model Mouse Using Knowledge Graphs: Combining Gene Expression, Orthology, and Disease Datasets. bioRxiv, 2023-08.
  17. Giacomelli, A., Massetti, L., Sabatini, F., & Maggi, E. (2016). Participatory dark sky quality monitoring from Italy: interactions between awareness raising and research. International Journal of Sustainable Lighting, 18, 40-48.
  18. Sailema, W. G. C., Olivares, T., & Delicado, F. (2022). Topologías en el Internet de las Cosas Médicas (IoMT), revisión bibliográfica. Revista Tecnológica-ESPOL, 34(4), 120-136.